{
    "clinical_study": {
        "@rank": "58530", 
        "arm_group": [
            {
                "arm_group_label": "Advagraf followed by Prograf", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Prograf followed by Advagraf", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the drug profiles (pharmacokinetics) and  effects\n      (pharmacodynamics) of Advagraf\u00ae and Prograf\u00ae on the kidneys."
        }, 
        "brief_title": "A Comparison of the Effects of Extended Release Tacrolimus (Advagraf\u00ae) vs. Immediate Release Tacrolimus (Prograf\u00ae) on Kidney Function in Healthy Male Volunteers", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "This is a 2 Period study.  In Period 1, subjects will be assigned randomly to receive\n      Advagraf\u00ae or Prograf\u00ae administered once or twice daily, respectively, for a period of 10\n      days.  In Period 2, subjects will be converted from Advagraf\u00ae to Prograf\u00ae or from Prograf\u00ae\n      to Advagraf\u00ae for 10 additional days of dosing.  Dose adjustments will be made based on the\n      monitoring of drug levels in blood."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Caucasian\n\n          -  No previous/current history of infection, cerebrovascular, neurological,\n             cardiovascular, endocrine, pulmonary, immunologic or metabolic disease or significant\n             systemic disease, glucose intolerance, gout or hematological disorder\n\n          -  Normal 12-lead Electrocardiogram (ECG)\n\n          -  Systolic blood pressure <140 mm Hg and diastolic blood pressure <90 mm Hg\n\n          -  Non-smoker within 3 months prior to screening\n\n          -  Willing to abstain from alcohol during the study\n\n        Exclusion Criteria:\n\n          -  Positive screen for illicit drug or alcohol consumption\n\n          -  Subject has hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or history\n             of cancer (excluding completely excised squamous or basal cell carcinoma)\n\n          -  Positive tuberculin skin test or known history of tuberculosis infection\n\n          -  Known history of serious head injuries, seizures or eating disorders\n\n          -  Body Mass Index <18.0 or >30.0\n\n          -  History of renal dysfunction, clinically significant creatinine or clinically\n             significant abnormal liver function tests, hemoglobin <130 g/L\n\n          -  Plasma donation \u2265 500 mL within 7 days prior to first dose of study drug, donation or\n             whole blood loss 50-499 mL within 30 days or \u2265 499 mL within 56 days prior to first\n             dose of study drug.\n\n          -  Drug or alcohol abuse within 1 year prior to study entry\n\n          -  Steroid injections within 12 weeks prior to first dose of study drug\n\n          -  Live vaccine within 7 days prior to first dose of study drug"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "19", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01681134", 
            "org_study_id": "FKC-016"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Advagraf followed by Prograf", 
                    "Prograf followed by Advagraf"
                ], 
                "description": "oral", 
                "intervention_name": "Advagraf\u00ae", 
                "intervention_type": "Drug", 
                "other_name": "tacrolimus XL, FK506E"
            }, 
            {
                "arm_group_label": [
                    "Advagraf followed by Prograf", 
                    "Prograf followed by Advagraf"
                ], 
                "description": "oral", 
                "intervention_name": "Prograf\u00ae", 
                "intervention_type": "Drug", 
                "other_name": "tacrolimus, FK506"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tacrolimus"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "tacrolimus", 
            "Advagraf\u00ae", 
            "Prograf\u00ae", 
            "Glomerular Filtration Rate", 
            "Effective Renal Plasma Flow", 
            "Pharmacokinetics", 
            "Pharmacodynamics"
        ], 
        "lastchanged_date": "November 6, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Toronto", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "M5V 2T3"
                }, 
                "name": "INC Research"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Comparison of Effects of Short-Term Steady State Low Dose Exposure of Extended Release (Advagraf\u00ae) and Immediate Release (Prograf\u00ae) Formulations of Tacrolimus on Renal Perfusion and Function in Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "Astellas Pharma Canada, Inc.", 
            "last_name": "Associate Director, Medical Affairs", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Estimated by aminohippurate sodium (PAH) clearance", 
            "measure": "Effective Renal Plasma Flow (ERPF)", 
            "safety_issue": "No", 
            "time_frame": "up to Day 20"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01681134"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Estimated by sinistrin clearance", 
            "measure": "Glomerular Filtration Rate (GFR)", 
            "safety_issue": "No", 
            "time_frame": "Pre-dose (Day -4), Day 10, Day 20"
        }, 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Canada, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}